AI platform models protein flexibility to accelerate drug design
Researchers developed an AI-driven drug discovery platform that models protein flexibility during molecular binding. The suite includes YuelDesign, YuelPocket and YuelBond.
CDK2
GeneRelated News
CDK Inhibitor Landscape: From Approved CDK4/6 Drugs to Next-Generation CDK2 Strategies
CDK4/6 inhibitors have transformed HR+/HER2− breast cancer treatment, while emerging resistance mechanisms are driving development of selective CDK2 inhibitors and dual CDK2/4 strategies to address treatment failure.